Abstract 2054
Background
Oncology patients with advanced disease frequently undergo Radiation to relieve symptoms such as pain and dyspnoea. These patients have been treated by different health professionals in multiple, complexed and long-term treatments. The goal of this study was to investigate the possibility to help and improve the quality of life of these patients.
Trial design
In the present study, 32 patients participated and were evaluated prospectively. The main criteria for their participation were the following: oncology patients >18 years old with a satisfactory level of verbal communication and advance cancer receiving radiotherapy. EORTC questionnaires (QLQ-C30) and questionnaire for problems and needs for palliative care PNCP-Center for the Quality of Care of the WOK research were used.The quality of life of these patients was assessed prior the beginning of the treatment and that was taken as a quality of life baseline level as well as at the end of their treatment. The present study was conducted from June 2018 to December 2018 in the Radiotherapy Department of "Hygeia" Hospital in Greece. Of the 32 patients who were evaluated 11 were women and 21 were men. Their average age was 65 years old. Also 84,4% of these patients had external help (family, caretaker). A significant improvement in the quality of life was observed only in patients who had home help for 4 hours daily (p.value 0,006).Men seemed to improve the quality of life after treatment (p.value 0,005).The patients reported their palliative care needs in the following rating scale: financial and phychological issues, autonomy, daily activities, spiritual issues, organic symptoms and need for information ,all of which will be presented in detail. Those who have difficulty completing tasks need or depent on others and ask for professional help (p.value 0,001)Radiation therapy alleviates the organic symptoms of patients with advanced disease, but it does not cover their needs that have become more important to them than their organic symptoms. Care for these patients needs a more specialized approach which incorporates the principles of palliative care.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
5877 - Efficacy of anti-PD(L)1 treatment in patients with metastatic urothelial cancer based on mRNA- and protein- based PD-L1 determination: Results from the multicentric, retrospective FOsMIC trial
Presenter: Jonas Jarczyk
Session: Poster Display session 3
Resources:
Abstract
5204 - A differential bladder microbiota composition is associated with tumor grade in bladder cancer.
Presenter: Monica Parra-Grande
Session: Poster Display session 3
Resources:
Abstract
4904 - Molecular characterization of metastatic urothelial carcinoma (mUC) in prior or current smokers (PCS) vs non-smokers (NS)
Presenter: Victor Sacristan Santos
Session: Poster Display session 3
Resources:
Abstract
5370 - Evaluation of different diagnostic methods for identification of FGFR alteration in advanced urothelial carcinomas: Proficiency Results based on multiple RNA extraction kits and mutation detection methods
Presenter: Veronika Weyerer
Session: Poster Display session 3
Resources:
Abstract
2579 - Title: Genomic characterization of non-schistosomiasis-related squamous cell carcinoma (NSR-SCC) of the urinary bladder: a retrospective study of potential prognostic and predictive biomarkers
Presenter: Esmail Al-ezzi
Session: Poster Display session 3
Resources:
Abstract
2203 - TiNivo: Tivozanib combined with nivolumab results in prolonged progression free survival in patients with metastatic renal cell carcinoma (mRCC). Final Results.
Presenter: Philippe Barthelemy
Session: Poster Display session 3
Resources:
Abstract
4712 - First-Line Pembrolizumab (pembro) Monotherapy for Advanced Non‒Clear Cell Renal Cell Carcinoma (nccRCC): Updated Follow-Up for KEYNOTE-427 Cohort B
Presenter: Cristina Suárez
Session: Poster Display session 3
Resources:
Abstract
2091 - First-Line Pembrolizumab (pembro) Monotherapy in Advanced Clear Cell Renal Cell Carcinoma (ccRCC): Updated Follow-Up For KEYNOTE-427 Cohort A
Presenter: James Larkin
Session: Poster Display session 3
Resources:
Abstract
2368 - Association Between Depth of Response and Overall Survival: Exploratory Analysis in Patients With Previously Untreated Advanced Renal Cell Carcinoma (aRCC) in CheckMate 214
Presenter: Viktor Grünwald
Session: Poster Display session 3
Resources:
Abstract
6008 - Quality of life in previously untreated patients with advanced renal cell carcinoma (aRCC) in CheckMate 214: updated results
Presenter: David Cella
Session: Poster Display session 3
Resources:
Abstract